Shedding of infectious SARS-CoV-2 from airways in hospitalized COVID-19 patients in relation to serum antibody responses - Glans, Hedvig; Gredmark-Russ, Sara; Olausson, Mikaela; Falck-Jones, Sara; Varnaite, Renata; Christ, Wanda; Maleki, Kimia T.; Karlberg, Maria Lind; Broddesson, Sandra; Falck-Jones, Ryan; Bell, Max; Johansson, Niclas; et al. (medRxiv, 2020)
To understand the risk of transmission of SARS-CoV-2 in hospitalized COVID-19 patients we simultaneously assessed the presence of SARS-CoV-2 RNA, live infectious virus in the airways, and virus-specific IgG and neutralizing antibodies in sera in 36 hospitalized COVID-19 patients. SARS-CoV-2 could be cultured from four patients, all with low or undetectable antibody response. Our data suggests that the level of SARS-CoV-2 antibodies may correlate to risk for shedding live SARS-CoV-2 virus in hospitalized COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementParts of this study was supported by Marianne and Marcus Wallenberg Foundation (Sara Gredmark-Russ), grants provided by region Stockholm (ALF project) (Sara Gredmark-Russ), grants from the Swedish Research Council (Anna Smed-Sorensen, Jonas Klinstrom) and the Swedish Heart and Lung Foundation (Anna Smed-Sorensen).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval, Sweden. Dnr: 2015/1949-31/4, Dnr: 2017/253-32, Dnr: 2018/382-32, Dnr: 2020-0055, Dnr: 2020-01757.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author (HG). The data are not publicly available due to restrictions e.g. their containing information that could compromise the privacy of research participants.